Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant

Bone Marrow Transplantation volume 25, pages 41–45 (2000)Cite this article

Abstract

We report 27 patients with relapsed acute or chronic leukemia who underwent a second hematopoietic stem cell transplant (HSCT) from a related or unrelated donor. Seventeen patients were diagnosed with acute myelogenous leukemia (AML), six with acute lymphocytic leukemia (ALL) and four with chronic myeloid leukemia (CML). Ages ranged from 22 to 49 years (median 37); 13 patients were female and 14 male. Relapse was diagnosed between 1 and 45 months after the first HSCT. Sixteen patients who relapsed had received an autologous transplant initially and 11 an allogeneic transplant. Ten patients relapsed within 6 months and 17 patients later than 6 months. Chemotherapy was used as reinduction for relapse after HSCT in 16 patients who had received an autologous transplant and in three who had received an allogeneic transplant, since the latter did not respond to reduction of immunosuppression to induce a graft-versus-leukemia (GVL) reaction. Five of these 19 patients (26%) achieved complete remission (CR), seven patients did not respond to chemotherapy and seven achieved a partial remission (PR). The stem cell source for the second HSCT included bone marrow (n = 12) and PBSC (n = 4) from genotypically identical unrelated donors, PBSC (n = 7) and bone marrow (n = 3) from related donors. Currently eight of the 27 patients are alive and disease-free after the second HSCT. One patient is alive and disease-free after two allogeneic transplants (day +1538), eight patients, who relapsed after an autologous transplant followed by an allogeneic transplant (days +248 to +1140), acute myeloid leukaemia (n = 6) and chronic myeloid leukemia (n = 2) are alive and disease-free. The overall disease-free survival is 30% (8/27). The overall disease-free survival of autologous transplant patients subsequently undergoing an allogeneic transplant is 43% (P = 0.049). It is suggested that a second HSCT is possible for patients with leukemia relapse following the first autologous transplant. A second transplant might also be offered to patients relapsing after the first allogeneic HSCT. Bone Marrow Transplantation (2000) 25, 41–45.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Donney K, Fisher LD, Appelbaum F . Treatment of adult acute lymphoblastic leukemia with allogenic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse and relapse free survival Bone Marrow Transplant 1991 7: 453–459

    Google Scholar 

  2. Wingard JR, Piantadosi S, Santos WG . Allogeneic bone marrow transplant for patients with high risk acute lymphoblastic leukemia J Clin Oncol 1991 8: 820–830

    Article  Google Scholar 

  3. Gale RP, Kersey JH, Bortin MM et al. Bone marrow transplantation for acute lymhoblastic leukemia Lancet 1983 2: 663–667

    CAS  PubMed  Google Scholar 

  4. Gratwohl A, Hermans J, Barrett AJ et al . Allogeneic bone marrow transplantation for leukemia in Europe. Report from the Working Party on Leukemia. European Group for Bone Marrow Transplantation Lancet 1988 i: 1375–1382

    Google Scholar 

  5. Sierra J, Storer B, Hanser JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemia burden, donor HLA-matching and marrow cell dose Blood 1997 89: 4226–4235

    CAS  PubMed  Google Scholar 

  6. Barrett A, Locatelli F, Treleaven JG et al. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission Br J Haematol 1991 79: 567–574

    Article  CAS  PubMed  Google Scholar 

  7. Atkinson K . Who should get a second marrow transplant? Bone Marrow Transplant 1992 10: 82–84

    PubMed  Google Scholar 

  8. Martino R, Badell I, Brunet S et al. Second bone marrow transplantation for leukemia in untreated relapse Bone Marrow Transplant 1994 14: 589–593

    CAS  PubMed  Google Scholar 

  9. Wagner JE, Vogelsang GB, Zehnbauer BA et al. Relapse of leukemia after bone marrow transplantation. Effect of second myeloablative therapy Bone Marrow Transplant 1992 9: 205–209

    CAS  PubMed  Google Scholar 

  10. Locatelli F . The role of repeat transplantation of haematopoietic stem cells and adoptive immunotherapy in treatment of leukemia relapsing following allogeneic transplantation Br J Haematol 1998 102: 633–638

    Article  CAS  PubMed  Google Scholar 

  11. Chiang KY, Weisdorf DJ, Davies SM et al. Outcomeof second bone marrow transplantation following a uniformconditioning regimen as therapy for malignant relapse BoneMarrow Transplant 1996 17: 39–42

    CAS  Google Scholar 

  12. Tsai, T, Goodman S, Saez R et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation Bone Marrow Transplant 1997 20: 859–863

    Article  CAS  PubMed  Google Scholar 

  13. Kröger N, Hoffknecht M, Hänel M et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose limiting radiation therapy Bone Marrow Transplant 1998 21: 1171–1175

    Article  PubMed  Google Scholar 

  14. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: the effect of leukemic burden, donor HLA-matching and marrow cell dose Blood 1997 89: 4226–4235

    CAS  PubMed  Google Scholar 

  15. Armitage P, Berry G . Statistical Methods in Medical Research Blackwell Science: Oxford 1987

    Google Scholar 

  16. Mrsic M, Horowitz MM, Atkinson K et al. Second HLA-identical sibling transplants for leukemia recurrence Bone Marrow Transplant 1992 9: 269–275

    CAS  PubMed  Google Scholar 

  17. Blau IW, Basara N, Serr A et al. A second unrelated bone marrow transplant: successful quantitative monitoring of mixed chimerism using a highly discriminative PCR-STR system Clin Lab Haematol 1999 21: 133–138

    Article  CAS  PubMed  Google Scholar 

  18. Sanders JE, Buckner CD, Clift RA et al. Second marrow transplants in patients with leukemia who relapse after allogeneic marrow transplantation Bone Marrow Transplant 1988 3: 11–19

    CAS  PubMed  Google Scholar 

  19. Basara N, Bischoff ME, Blau IW et al. A second unrelated bone marrow transplant with an unrelated donor marrow: treatment of a patient with relapsed leukemia Bone Marrow Transplant 1998 21: 291–293

    Article  CAS  PubMed  Google Scholar 

  20. Champlin R, Giralt S, Gajewski J et al. T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation Acta Haematol 1996 95: 157–163

    Article  CAS  PubMed  Google Scholar 

  21. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusion in marrow grafted patients Blood 1995 86: 2041–2050

    CAS  PubMed  Google Scholar 

  22. Khouri IF, Keating M, Körbling M et al. Transplant lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies J Clin Oncol 1998 16: 2817–2824

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic for Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany

    IW Blau, N Basara, M Bischoff, S Günzelmann, E Römer, D Kirsten, B Schmetzer, MG Kiehl & AA Fauser

Authors
  1. IW Blau
    View author publications

    Search author on:PubMed Google Scholar

  2. N Basara
    View author publications

    Search author on:PubMed Google Scholar

  3. M Bischoff
    View author publications

    Search author on:PubMed Google Scholar

  4. S Günzelmann
    View author publications

    Search author on:PubMed Google Scholar

  5. E Römer
    View author publications

    Search author on:PubMed Google Scholar

  6. D Kirsten
    View author publications

    Search author on:PubMed Google Scholar

  7. B Schmetzer
    View author publications

    Search author on:PubMed Google Scholar

  8. MG Kiehl
    View author publications

    Search author on:PubMed Google Scholar

  9. AA Fauser
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blau, I., Basara, N., Bischoff, M. et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 25, 41–45 (2000). https://doi.org/10.1038/sj.bmt.1702101

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702101

Keywords

This article is cited by

Search

Advanced search

Quick links